Memorial Sloan Kettering Cancer Center

https://www.mskcc.org/healthcare-professionals

Refer a Patient to MSKCC: mskcc.org/refer

 

Genitourinary
25:32

Memorial Sloan Kettering Cancer Center

Multidisciplinary Approaches for Muscle Invasive Bladder Cancer

FEATURING Bernard Bochner
  • 201 views
  • July 9, 2024
  • 2
29:46

Memorial Sloan Kettering Cancer Center

Clinical Perspectives on Managing Hereditary Kidney Cancer

FEATURING Jonathan Coleman
  • 53 views
  • July 9, 2024
06:55

Insights from 2024 ASCO® GU Annual Meeting

ASCO® GU 2024 Insights: "HER2 and PD-L1 Immunohistochemistry Expression, and HER2 Genomic Alterations - Associations and Clinical Outcomes for Advanced Bladder Cancer"

FEATURING David Aggen
  • 112 views
  • February 20, 2024
  • 1
08:56

Insights from 2023 ESMO Annual Meeting

ESMO 2023 Insights: "MEDI5752 (Volrustomig) in the 1L Treatment of Patients With Advanced ccRCC"

FEATURING Martin Voss
  • 132 views
  • November 24, 2023
24:28

OncoAlert

The Best of GU Radiation Oncology

FEATURING Sean McBride
  • 277 views
  • March 1, 2023
  • 4
46:48

University of Colorado Cancer Center

Theranostics and the Changing Face of Prostate Cancer

FEATURING Michael Morris
  • 248 views
  • October 21, 2022
08:05

ASCO 2022 Conference Coverage

ASCO 2022: A Phase II Study of Gem + Cis Chemo in MIBC With Bladder Preservation for Patients Whose Tumors Harbor Deleterious DNA Damage Response Gene Alterations (Alliance A031701)

FEATURING Gopa Iyer
  • 131 views
  • June 8, 2022
44

Memorial Sloan Kettering Cancer Center

Lecture Summary - Results of Phase II Clinical Trial of Cabozantinib + Nivolumab for Advanced ncRCC

FEATURING Chung-Han Lee
  • 18 views
  • May 13, 2022
07:31

Memorial Sloan Kettering Cancer Center

Results of Phase II Clinical Trial of Cabozantinib + Nivolumab for Advanced ncRCC

FEATURING Chung-Han Lee
  • 76 views
  • April 26, 2022
  • 1
06:49

ASCO Genitourinary Cancers Symposium

ASCO GU 2022 on Gem & Cis as Neoadjuvant Chemo in High-Grade UTUC: Final Results of a Multicenter Prospective Phase II Clinical Trial

FEATURING Wesley Yip
  • 92 views
  • February 28, 2022
06:24

ecancer

ASCO 2021 Update on mCRPC: VISION Trial Data on Lutetium-177-PSMA-617

FEATURING Michael Morris
  • 39 views
  • September 2, 2021
  • 1
04:46

Memorial Sloan Kettering Cancer Center

2020 Update on mRCC: Lenvatinib + Pembro After CPIs: Is There a Benefit to PFS and What Are the Response Rates?

FEATURING Chung-Han Lee
  • 4 views
  • September 18, 2020